CSJ-137 is under clinical development by Novartis and currently in the Phase I in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.
According to GlobalData, the latest event to affect CSJ-137’s likelihood of approval (LoA) and phase transition for Iron Deficiency Anemia took place on 19 Apr 2021, which increased the likelihood that the drug progresses to the next phase in its clinical pathway and increased the likelihood of final approval for this indication.
GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their CSJ-137 Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.
CSJ-137 is under development for the treatment of functional iron-deficiency anemia in erythropoietin-treated chronic hemodialysis patients. It is administered through intravenous route.
Novartis is a healthcare company that focuses on the discovery, development, manufacture and marketing of prescription and generic pharmaceutical products and eye care products. It provides drugs for the treatment of cancer, cardiovascular diseases, dermatological conditions, neurological disorders, ophthalmic and respiratory diseases, immune disorders, and infections, among others. The company offers generic medicines and biosimilars through Sandoz. Novartis conducts research in various disease areas through The Novartis Institutes for BioMedical Research (NIBR). The company operates through a network of subsidiaries and offices across the Americas, Europe, the Middle East, Africa, and Asia-Pacific. Novartis is headquartered in Basel, Switzerland.
Quick View CSJ-137 LOA Data
|Highest Development Stage|